Reduction of malaria transmission to Anopheles mosquitoes with a six-dose regimen of co-artemether.

ABSTRACT:

Background

Resistance of malaria parasites to chloroquine (CQ) and sulphadoxine-pyrimethamine (SP) is increasing in prevalence in Africa. Combination therapy can both improve treatment and provide important public health benefits if it curbs the spread of parasites harbouring resistance genes. Thus, drug combinations must be identified which minimise gametocyte emergence in treated cases, and so prevent selective transmission of parasites resistant to any of the partner drugs.

Methods and findings

In a randomised controlled trial, 497 children with uncomplicated falciparum malaria were treated with CQ and SP (three doses and one dose respectively; n = 91), or six doses of artemether in fixed combination with lumefantrine (co-artemether [Coartem, Riamet]) (n = 406). Carriage

SUBMITTER: Sutherland CJ 

PROVIDER: S-EPMC1087200 | biostudies-literature | 2005 Apr

REPOSITORIES: biostudies-literature